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Abstract
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being 
intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-
neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported 
in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR 
inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect 
against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if 
the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) 
recipients with a pre-transplant diagnosis of HCC.
Methods/Design: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-
inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC 
diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-
inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free 
immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 21/2 -year recruitment phase 
is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus 
use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated 
trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine 
Transplant Association; 13 countries within Europe, Canada and Australia are participating.
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Page 2 of 8Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously 
providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-
transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive 
outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC.
Trial Register: Trial registered at http://www.clinicaltrials.gov: NCT00355862
(EudraCT Number: 2005-005362-36)
Background
Patients with HCC that receive a LT in an attempt to cure
their cancer and any superimposed liver disease face at
least two major issues. First, the patient requires ade-
quate immunosuppressive medication to avoid rejection
of the liver allograft. Second, the patient has a risk that
the HCC recurrence could recur, especially when in an
immunosuppressed state. Even when restricting LT to
patients with limited tumour expansion (e.g. Milan Crite-
ria [1]), some HCCs recur. Furthermore, a significant
number of pre-LT analyses of tumour extent are underes-
timated according to pathologic reports on explanted liv-
ers, leaving certain patients at a particularly high risk for
HCC recurrence.
Adding to the problem of HCC recurrence, immuno-
suppressive agents used to prevent allograft rejection are
generally regarded as tumourogenic, or at least permis-
sive of cancer development. It is particularly notable that
the most commonly used immunosuppressive class of
compounds in LT patients, calcineurin inhibitors
(cyclosporine and tacrolimus), have been implicated to
support tumour formation. Cyclosporine has been shown
in vitro to enhance cancer cell invasiveness [2] and sup-
port angiogenesis accompanying tumours [3,4]. It has
also been reported that cyclosporine inhibits DNA repair
mechanisms [5], potentially promoting tumour develop-
ment. Regarding LT, cyclosporine has been shown to pro-
mote liver tumour growth and recurrence in an
experimental rat model [6]. In other experimental stud-
ies, a higher proliferation rate of human hepatoma cells
could be demonstrated in the presence of another cal-
cineurin inhibitor, tacrolimus [7]. It remains, however,
unproven whether calcineurin inhibitors actually result in
a higher HCC recurrence in the setting of LT.
A new view towards this "old problem" of HCC recur-
rence is supported by recent studies showing that one
class of immunosuppressants, mTOR inhibitors, is capa-
ble of not only inhibiting immune responses against
transplanted allografts, they may also be potent antineo-
plastic agents. Rapamycin, as the first described mTOR
inhibitor, has strong antiangiogenetic effects that inhibit
tumour growth in numerous experimental models [3,4,8].
Indirect inhibition of tumor metastasis has also been
reportedly due to increased E-cadherin expression on
tumour cells [9]. Not only does rapamycin inhibit tumour
growth indirectly, cancer cells themselves are inhibited
directly by their variable dependence on the mTOR path-
way for cell growth and survival [10]. Interestingly, HCC
tends to be highly vascularised [11], suggesting a poten-
tial susceptibility to rapamycin. Moreover, experimental
models indicate that the mTOR signalling pathway is util-
ised by hepatic tumour cells [12].
From a clinical perspective, mTOR inhibitors have
begun to show efficacy with some types of cancer, includ-
ing especially advanced renal cell carcinoma [13,14]. Lit-
tle information is available in the context of organ
transplantation. While early indications from transplant
registry data [15], and from studies not directed at deter-
mining tumour development, suggest a general decrease
in cancer with mTOR inhibitors, no prospective ran-
domised data has yet confirmed this idea. Most data pub-
lished with respect to tumour development in transplant
recipients has been with the mTOR inhibitor, sirolimus.
Although not powered for an oncologic endpoint, studies
using sirolimus suggest skin cancer, and other malignan-
cies may be fewer in transplant recipients [16]. Small
non-randomised uncontrolled pilot trials and retrospec-
tive analyses also hint that sirolimus may improve the
outcome for LT patients with a pretransplant diagnosis of
HCC [17,18], regarding both tumour recurrence and a
more benign course of renewed HCC disease [19]. Unfor-
tunately, these ostensible effects can only be confirmed in
a controlled prospective randomised clinical trial.
Based on these experimental and clinical observations,
we have designed a clinical trial protocol with the pur-
pose of testing whether the mTOR inhibitor sirolimus can
improve HCC-free survival after LT. We predict that
patients treated with sirolimus will experience an
improved HCC-free survival.
Methods/Design
Basic protocol overview
This is an open-labeled, randomised, prospective multi-
center clinical trial comparing sirolimus-containing ver-
sus mTOR-inhibitor-free immunosuppression in patients
undergoing LT for HCC. We have named the trial the
"SiLVER Study", referring to the use of sirolimus in LT
patients with HCC. The study is planned for 8 years in
total, consisting of a 3-year enrolment period and a 5-
year follow-up. Patients with a histologically proven HCC
either within Milan Criteria or with extended criteria will
be randomised into 2 groups between day 22 and 42
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a centre-specific mTOR-inhibitor-free immunosuppres-
sive protocol. This control arm will be compared to a sec-
ond group of patients that will be treated with the centre-
specific protocol for the first 4-6 weeks, at which time
sirolimus will be incorporated (between day 29 and day
42) into the regime either as a monotherapy, or as a com-
bination therapy with non-mTOR-inhibitor-based immu-
nosuppression (Figure 1).
Notably, HCC staging will be assessed in the explanted
liver to determine the actual extent of tumor presence.
This information will be used with the pre-LT data to
determine if the patient is to be stratified into a high or
low risk group, based primarily on fulfilment of Milan
Criteria.
Inclusion criteria
The study includes all patients eligible for LT as outlined
by each of the participating centres, including deceased
whole-allograft and split-liver donors, as well as living
donors.
General inclusion criteria are: age over 18 years, histo-
logically proven HCC before randomisation and signed,
written informed consent given by the patient. Individual
patients who were treated pre-LT for histologically
proven HCC, for example by chemoembolisation, radiof-
requency ablation, or percutaneous ethanol instillation,
may show tumour reduction, or even complete necrosis,
after posttransplant histological staging in the explanted
liver. If there is complete tumour necrosis, histological
confirmation of HCC post-LT will not be possible. In
these cases, patients with a pretransplant histological
diagnosis of HCC may still be included in the study. How-
ever, complete biological tumour response patients will
be down-staged and therefore stratified into the group
considered within Milan criteria. In all patients with a
pre-LT histological proof of HCC, and an incomplete
tumour response following pretreatment, stratification
will be solely performed according to the final postopera-
tive histology. For example, in the case of pre-LT diagno-
sis of an HCC outside the Milan criteria, and subsequent
post-LT pathology revealing reduced tumour extent
Figure 1 Inclusion and Randomisation Scheme.
HCC-diagnosis
LT AND histological diagnosis of HCC
4 – 6 weeks (mTOR-Inhibitor-free)
Arm 1
mTORi-free IS
Arm 2
Sirolimus-
containing IS
Disease free survival (event-based analysis)
IS=Immunosuppression
Randomisation
Schnitzbauer et al. BMC Cancer 2010, 10:190
http://www.biomedcentral.com/1471-2407/10/190
Page 4 of 8within the Milan criteria, final stratification will be per-
formed according to the post-LT histology report.
Exclusion criteria
Patients with extrahepatic non-HCC malignancies within
the past 5 years (excluding successfully treated squamous
cell carcinoma and basal cell carcinoma of the skin) will
be excluded. Multiple-organ recipients, patients with a
known hypersensitivity to sirolimus or its derivates,
hyperlipidemia refractory to medical management, evi-
dence of local or systemic infection, HIV, platelets
<75,000/nl, women of child-bearing potential not willing
to take contraception, patients with extrahepatic HCC
tumour manifestation, and patients with a psychological,
familial, sociologic or geographic condition potentially
hampering compliance with the study protocol and fol-
low-up schedule or under guardianship (e.g. individuals
who are not able to freely give their informed consent),
and patients receiving mTOR inhibitors prior to day 29
after LT will also be excluded.
Study objectives
Our hypothesis is that sirolimus use in the test arm of the
study will improve HCC-free survival in this LT popula-
tion. The primary endpoint in this trial is HCC recur-
rence-free patient survival with sirolimus-containing
versus mTOR-inhibitor-free immunosuppression in
patients undergoing LT for HCC. Secondary endpoints
will be patient overall survival, incidence of de novo
malignancies, liver allograft and kidney function, HCV
and HBV recurrence, time to HCC recurrence, tumour
number and size at the time of recurrence, tumour pro-
gression rate, and HCC-free, as well as, overall -survival
in high and low -risk groups.
Randomisation and treatment scheme
Patients will be randomised via an interactive voice
response system (IVRS) into one of the two treatment
arms after histologically proven HCC. After the patient is
assigned to a treatment group, a code to uniquely identify
the patient (Patient ID) and the assigned treatment group
is transmitted via fax. In treatment arm 1, patients are
treated with the centre-specific immunosuppressive pro-
tocol, excluding the use of any mTOR-inhibitor medica-
tions. Steroid reduction is encouraged by 3 months post-
LT. In treatment arm 2, application of sirolimus is started
between day 29 and 42 after LT with a loading dose of 5
mg/d, and 2 mg/d thereafter. The first sirolimus trough
level is measured after 3 to 4 days, followed by trough lev-
els once a week for 4 weeks and twice a month thereafter.
The desired trough level for sirolimus is 4-10 ng/ml.
Simultaneously, the use of mycophenolic acid prodrugs
(mycophenolate mofetil, Roche; enteric-coated mycophe-
nolate sodium, Novartis) and of calcineurin inhibitors
should be reduced by 50%. Steroid reduction by 3 months
is encouraged. The ideal long term, but not obligate, goal
is sirolimus mono-therapy in arm 2.
Follow-up and documentation
In the first year after LT all patients will be followed-up
after month 1, 3, 6, 9 and 12. Thereafter, patients are fol-
lowed-up every 6 months. Sirolimus levels in patients
within arm 2 will be tested and adjusted if need be at each
follow-up date.
In general, regular documentation includes data on
graft survival, graft dunction as measured by laboratory
values, incidence of clinically-diagnosed and biopsy
proven acute graft rejection, severity of rejection (histo-
logical grade), incidence of premature withdrawal from
study medication for any reason, changes in glucose or
lipid metabolism, renal function, changes in systolic and/
or diastolic blood pressure, adverse events, infectious
complications, wound-healing disturbances, haematolog-
ical toxicity, gastrointestinal side-effects, thrombembolic
complications, tumour recurrence information and
patient survival.
If a patient should miss two consecutive follow-up visits
and the investigator cannot establish contact with the
patient, the status of the patient will be set to 'lost-to-fol-
low-up'. If the last contact was prior to the diagnosis of a
recurrence event, recurrence-free survival time will be
censored using the date of the last contact. If contact with
the patient can be re-established, the status for survival
time will be reset to alive. However, recurrence-free sur-
vival time and accompanying censoring status will
remain. If the date of a patient's death is documented, the
status will be "dead".
Endpoint definition
HCC recurrence-free survival (RFS) is specifically
defined as the time interval between the date of LT and
the date of HCC recurrence or death (as first event);
patients who are alive and recurrence-free at the time of
analysis will be censored for RFS at the time of their last
contact. HCC recurrence is defined as either histologi-
cally-proven tumour recurrence, or unequivocal tumor
recurrence determined by the Barcelona Criteria (Barce-
lona-2000 EASL Conference). Date of recurrence is
defined as the first day of tumor suspicion. Clinical evi-
dence for HCC recurrence including β-symptoms, weight
loss, inappetence, pruritis, and ascites are considered sus-
picious signs and are followed up by definitive diagnostic
action in accordance with the Barcelona Criteria. Recur-
rence of HCC can therefore be determined during the
entire follow-up period, and not only at protocol-
assigned visits.
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The SiLVER Study is an investigator-initiated trial. Pre-
liminary investigator meetings to plan the specifics of the
trial protocol were organised by the Department of Sur-
gery, University of Regensburg (University Hospital
Regensburg). Indeed, University Hospital Regensburg is
the sponsor of the study. Funding aid is through a grant
provided by Pfizer (Collegeville, PA, USA). Contract
research organisation (CRO) services for site monitoring
and regulatory affairs are provided by Chiltern Interna-
tional, Bad Homburg, Germany. The eCRF and IVRS-ser-
vices are provided by ClinIT, Freiburg, Germany. Drug
storage, re-labelling and distribution tasks are outsourced
to B&C Clinipack, Wavre, Belgium. Statistical research
was performed within the Department of Surgery, Uni-
versity Hospital Regensburg, and the statistical plan was
developed together with the Regensburg Center for Clini-
cal Studies.
Participating Centers
Major liver transplant centres from Europe, Australia and
Canada are participating. In total, 45 sites from 13 coun-
tries (Germany, Austria, France, Spain, Italy, Belgium,
Netherlands, UK, Sweden, Norway, Finland, Australia
and Canada) have committed to the study. Multiple cen-
tres were required for this study, since enrolling the
planned number of LT patients with HCC could only be
accomplished through a broad-based concerted effort.
Drug supply
One mg and 2 mg sirolimus (Rapamune) blisters, as well
as a single 5 mg starting dose pack, is supplied as study
medication to the participating centres via B&C Clini-
pack.
On-site monitoring
During recruitment and follow-up of patients, regular
monitoring of safety and endpoint data is performed
according to good clinical practice (GCP) guidelines.
Data management is performed by ClinIT and by central
monitoring at the sponsoring institution.
Ethics and safety
Most recently, Protocol Version 9 has been approved by
the responsible national/local ethics board for each of the
sites participating in the study. We have recently
described the ethical review process for our study, in
detail [20]. The study protocol has been approved by eth-
ics committees serving the following institutions: (Ger-
many) University Hospital Regensburg, University
Hospital of Schleswig-Holstein Campus Kiel, University
Leipzig, University Hospital Tübingen, Charité Univer-
sitätsmedizin Berlin, Munich University Grosshadern
Campus, University Hospital Essen, Johann Wolfgang
Goethe University Frankfurt, Medizinische Hochschule
Hannover, Ruprecht-Karls-University Heidelberg,
Johannes Gutenberg University Mainz Hospital, Münster
University, University Hospital of the Friedrich-Schiller-
University Jena; (Austria) Medical University Innsbruck,
Medical University Vienna; (Spain) University Hospital
Puerta da Hierro Madrid, University Hospital Vall
d'Hebron Barcelona; (Sweden) Karolinska University
Hospital Huddinge Stockholm, The Rikshospitalet Uni-
versity Hospital Oslo; (Netherlands) Leiden University
Medical Centre, University Medical Center Groningen;
(Belgium) Ghent University Hospital Medical School,
University Hospital Leuven, Université Catholique de
Louvain Brussels; (Italy) University Hospital Bologna,
Azienda Ospedaliera "Ospedali Riuniti" Bergamo, Uni-
versity Hospital of Padua, San Martino University Hospi-
tal Genova, National Cancer Institute Milan, Fondazione
IRCCS Ospedale Maggiore Policlinico Mangiagalli e
Regina Elena Milano; (Finland) Helsinki University Hos-
pital; (Canada) University of Alberta Edmonton, Univer-
sity of Montreal; (Australia) Royal Prince Alfred Hospital
Camperdown NSW Sydney. National central ethics com-
missions in Great Britain (Cambridgeshire Research Eth-
ics Committee - formerly Eastern Multi Center Research
Ethics Committee) and France (the Consultative Com-
mittee for the Protection of People in Biomedical
Research CCPPRB Créteil- Henri Mondor) approved the
study protocol for the participating centres in these two
countries.
The study complies with the Declaration of Helsinki
and the principles of Good Clinical Practice (GCP) guide-
lines. Informed consent is obtained from each patient in
written form prior to randomisation. The patient is
informed about the nature, duration and possible conse-
quences of the trial by a medical doctor familiar with the
study. Patient safety and all potential threats for the
patients are being monitored once a year by an indepen-
dent data safety monitoring board (DSMB), or addition-
ally at the discretion of the DSMB or Sponsor; the DSMB
also will confidentially evaluate the primary endpoint
data. Qualified personnel at sponsor site also meet every
three months to review safety data, including adverse
events (AE) and serious adverse events (SAE). Any infor-
mation deemed to potentially affect the safety of the trial
will be brought to the attention of the DSMB.
Sample size
Sample size was calculated using the primary endpoint of
RFS assuming proportional hazards and exponential dis-
tributions of RFS. RFS time distributions of combined
high and low risk patients in the two treatment groups
will be compared using a two-sided (stratified) log-rank
test at a 0.05 significance level. A 5-year RFS rate of 60%
Schnitzbauer et al. BMC Cancer 2010, 10:190
http://www.biomedcentral.com/1471-2407/10/190
Page 6 of 8(or equivalently an event rate of 40%) in patients treated
with mTOR-inhibitor-free immunosuppression is
expected. An increase to a 5-year RFS rate of 72% (or
equivalently a decrease to an event rate of 28%) due to
sirolimus-containing immunosuppression is assumed.
The improvement in 5-year RFS rate from 60% to 72% (or
equivalently a decrease in 5-year recurrence event rate
from 40% to 28%) corresponds to a hazard ratio of 0.643
and is considered as clinically relevant. For detecting a
HR of 0.643 with a power of 1-β = 0.80 in the three-stage
group sequential design with an α spending function of
the O'Brien and Fleming type, it is necessary to observe
164 events (HCC recurrences or deaths). Assuming an
accrual time of 2 1/2 years and a follow-up time of at least
5 years from the last patient recruited, a total of 405
patients are expected to yield the necessary number of
events. With a lost to follow-up rate of about 20%, a total
of 510 patients (255 per treatment group) are required.
Statistical evaluation
The problem is statistically formulated as a test of the null
hypothesis H0: θ = 1 versus the alternative hypothesis H1:
θ ≠ 1, where the hazard ratio (HR) is defined as the risk of
recurrence in the sirolimus-containing immunosuppres-
sion group divided by the risk of recurrence in the
mTOR-inhibitor-free immunosuppression group. Rejec-
tion of the above null hypothesis suggests that there is a
statistically significant difference between the mTOR-
inhibitor-free immunosuppression and the sirolimus-
containing immunosuppression. An HR of less than 1
indicates superiority of sirolimus-containing immuno-
suppression.
RFS distribution and median RFS time will be esti-
mated for the two treatment arms using the Kaplan-
Meier method. The two-sided, (stratified) log-rank test
will be applied to test the RFS time null hypothesis
assuming proportional hazard rates at a 0.05 significance
level. Primary analysis will be based on the intention-to-
treat analysis set, however, to assess the robustness of the
results, a sensitivity analysis will be conducted on a per
protocol analysis set. Interim analyses will be performed
for ethical and practical reasons. The confirmatory analy-
sis of the primary endpoint will be done using a group
sequential analysis plan that is based on the number of
observed events. A design with a maximum of three
stages was chosen, whereby two interim analyses fol-
lowed by one final analysis are planned after 55, 109, and
164 events, respectively.
Secondary endpoints will be analyzed in purely an
exploratory manner. As part of this secondary analysis,
we will compare RFS in two cohorts of patients with dif-
ferent disease-free and overall survival probabilities.
Patients with HCC and cirrhosis within the Milan criteria
will be defined as "low-risk" patients, whereas patients
with HCC extending beyond Milan criteria, patients
undergoing salvage transplantation or an HCC in non-
cirrhotic liver, will be defined as "high-risk".
Discussion
Hepatic cancer recurrence continues to be a serious con-
sideration in patients receiving a LT for HCC. Early 2003
ELTR data showed a 5-year patient overall survival for
hepatic malignancy (primarily HCC) of merely 53%, com-
paring poorly with data from non-cholestatic liver cirrho-
sis of 74% and even acute liver failure of 62%. Since the
landmark publication in 1996 by Mazzaferro et al., many
centres have restricted their indication for HCC-related
LT due to clinical criteria based on tumour size and num-
ber ('Milan Criteria'), and other similar systems have
since been used [21]. With these improved criteria, sin-
gle-centre data do indeed show a significant improve-
ment in both disease-free and overall survival following
LT for HCC. Nonetheless, recurrences of HCC are not
eliminated even with restricting tumour size and number,
and importantly, pre-transplant evaluations of tumour
extent many times are underestimated, leading to a risk
for HCC recurrence in this transplanted subpopulation.
Considering the persistence of this problem, and intrigu-
ing new data that mTOR inhibitors at immunosuppres-
sive doses have potential anticancer effects, we took the
initiative to rigorously test the hypothesis that introduc-
tion of the mTOR inhibitor sirolimus could further
improve disease-free survival in typical LT patients with a
history of HCC.
Among the important considerations when designing
this trial was the inclusion of both patients with a low and
high risk for HCC recurrence. After much debate, our
study group concluded that all patients that would nor-
mally be transplanted should be included into the study.
With this practical approach, we could answer the ques-
tion whether the typical HCC group eligible for LT, as a
whole (including both low and later discovered high risk
patients), would benefit from an immunosuppressive
therapy containing sirolimus. Deciding to primarily anal-
yse HCC RFS was another critical point. Our reasoning
for this choice was that it could be possible to decrease
HCC recurrence with sirolimus, but if other unforeseen
complications of this therapy were eventually found to
reduce 5-year survival, in the end there would be no over-
all benefit to the patient; clearly, our study aims for an
overall benefit to the patient on the long-term. Finally, we
would also like to add that our protocol design is aimed
for practical implementation. Essentially, we will compare
a "non-mTOR inhibitor" containing immunosuppressive
regimen (arm 1) to a regimen that contains the mTOR
inhibitor sirolimus. Our approach considers the wide-
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regarding proper and safe immunosuppression following
LT. Each centre is basically allowed to use their standard
regimen, as long as mTOR inhibitors are not used in arm
1 and sirolimus is used in arm 2, on an intention-to-treat
basis. Experimental work [3], and registry data [15], sup-
port the contention that mTOR inhibitors maintain their
anticancer effects even in the presence of other immuno-
suppressants.
The SiLVER Study is the first prospective randomised
controlled international trial which evaluates HCC recur-
rence in patients normally eligible for LT. If our hypothe-
sis is correct that mTOR inhibition with sirolimus can
improve RFS, while simultaneously providing adequate
immunosuppression, patients with HCC that receive a LT
could expect a longer and better quality of life.
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